en · de · es
creatine-notes.peptides8425.com › News › Background And Research Context — Background and Details

Background And Research Context — Background and Details

By Editorial Desk · published 2026-07-07 · last reviewed 2026-08-01 · News

This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Related pages on this site

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Background and Development History

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Background from the literature

==== Cossack autonomies in Don, Kuban and North Caucasus ==== Soon after the Bolsheviks seized power in Petrograd on 7–8 November 1917, most Cossack atamans and their government refused to recognize the legitimacy of the new regime. The Don Cossack ataman, Aleksey Kaledin, went as far as to invite opponents of the Bolsheviks to the Don Host. But the position of many Cossack governments was far from secure, even within the boundaries of their hosts. In some areas, soviets formed by outlanders and soldiers rivaled the Cossack government, and ethnic minorities also tried to acquire a measure of self-rule. Even the Cossack communities themselves were divided, as the atamans tended to represent the interests of prosperous landowners and the officer corps. Poorer Cossacks, and those serving in the army, were susceptible to Bolshevik propaganda promising to spare "toiling Cossacks" from land appropriation. The unwillingness of rank-and-file Cossacks to vigorously defend the Cossack government enabled the Red Army to occupy the vast majority of Cossack lands by late spring of 1918. But the Bolsheviks' policy of requisitioning grain and foodstuffs from the countryside to supply Russia's starving northern cities quickly fomented revolt among Cossack communities. These Cossack rebels elected new atamans and made common cause with other anticommunist forces, such as the Volunteer Army in South Russia. Subsequently, the Cossack homelands became bases for the White movement during the Russian Civil War.

Microsomal glutathione S-transferase 2 is an enzyme that in humans is encoded by the MGST2 gene. The MAPEG (Membrane-Associated Proteins in Eicosanoid and Glutathione metabolism) family consists of six human proteins, several of which are involved in the production of leukotrienes and prostaglandin E, important mediators of inflammation. This gene encodes a protein that catalyzes the conjugation of leukotriene A4 and reduced glutathione to produce leukotriene C4.

Another aspect that distinguishes sortases in general is that they have a very specific targeting for their substrate, as sortases have generally two functions, the first is the fusing of proteins to the cell wall of the bacteria and the second is the polymerization of pilin. For the process of localization of proteins to the cell wall there is three-fold requirement that the protein contain a hydrophobic domain, a positively charged tail region, and final specific sequence used for recognition. The best studied of these signals is the LPXTG, which acts as the point of cleavage, where the sortase attacks in between Thr and Gly, conjugating to the Thr carboxyl group. Then the thioester is resolved by the transfer of the peptide to a primary amine, and this generally has a very high specificity, which is seen in the example of B. cereus where the sortase D enzyme helps to polymerize the BcpA protein via two recognition signals, the LPXTG as the cleavage and thioester forming point, and the YPKN site which acts as the recognition signal as where the isopeptide will form. While the particulars may vary between bacteria, the fundamentals of sortase enzymatic chemistry remain the same. The next case is that of Transglutaminases (TGases), which act mainly within eukaryotes for fusing together different proteins for a variety of reasons such as a wound healing or attaching proteins to lipid membranes. The TGases themselves also contain their own 'catalytic triad' with Histidine, Aspartate, and Cysteine.

Sources: en.wikipedia.org

Further detail

== Applications == Capillary electrophoresis may be used for the simultaneous determination of the ions NH4+,, Na+, K+, Mg2+ and Ca2+ in saliva. One of the main applications of CE in forensic science is the development of methods for amplification and detection of DNA fragments using polymerase chain reaction (PCR), which has led to rapid and dramatic advances in forensic DNA analysis. DNA separations are carried out using thin CE 50-mm fused silica capillaries filled with a sieving buffer. These capillaries have excellent capabilities to dissipate heat, permitting much higher electric field strengths to be used than slab gel electrophoresis. Therefore, separations in capillaries are rapid and efficient. Additionally, the capillaries can be easily refilled and changed for efficient and automated injections. Detection occurs via fluorescence through a window etched in the capillary. Both single-capillary and capillary-array instruments are available with array systems capable of running 16 or more samples simultaneously for increased throughput. A major use of CE by forensic biologists is typing of STR from biological samples to generate a profile from highly polymorphic genetic markers which differ between individuals. Other emerging uses for CE include the detection of specific mRNA fragments to help identify the biological fluid or tissue origin of a forensic sample.

=== Music === Season 3 is the only Euphoria season not scored by British composer Labrinth. On July 23, 2025, he announced he was working with German composer Hans Zimmer for the season. But on March 13, 2026, Labrinth posted an Instagram story that read, "Fuck Columbia. Double Fuck Euphoria. I'm out. Thank you and good night." Labrinth removed all his music from the show, leaving Zimmer as the sole music composer.

Since then, the number of known CPPs has expanded considerably, and small molecule synthetic analogues with more effective protein transduction properties have been generated. A recent discovery found that Papillomaviridae, such as the human papillomavirus, use CPPs to penetrate the intracellular membrane to trigger retrograde trafficking of the viral unit to the nucleus.

=== Schizophrenia === Persistent KOR signaling has been implicated in the pathophysiology of schizophrenia, in the generation of both positive and negative symptoms, and as an explanation for treatment-resistant psychosis. Mechanistically, chronic KOR activation produces long-term sensitization of dopamine D2 receptors in the striatum, which manifests as supersensitized D2 receptor states that amplify phasic dopamine signaling and hyperresponsivity to dopaminergic stimuli. This mechanism could interact with the underlying excessive striatal dopamine transmission in schizophrenia, potentiating positive symptoms including delusions and hallucinations, and explaining why dopamine D2 receptor antagonists (antipsychotics) remain effective. Apart from striatal mechanisms, KOR signaling modulates cortical glutamate and GABA homeostasis through KOR activation on GABAergic terminals of dynorphin-expressing neurons in prefrontal cortex which suppresses GABA release and disrupting the balance of cortical inhibition-excitation that might drive cognitive dysfunction and negative symptoms. Thus, KOR antagonism may provide a complementary strategy to D2 antagonism by simultaneously reducing D2 receptor sensitization to normalize striatal dopamine responsivity and restoring cortical inhibition-excitation balance to ameliorate cognitive dysfunction. The receptor availability also predicts severity of anhedonia in schizophrenia.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network